Compare STERIS Plc (Ireland) with Similar Stocks
Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 9.63
2
Healthy long term growth as Net Sales has grown by an annual rate of 13.16% and Operating profit at 12.29%
3
The company has declared Positive results for the last 4 consecutive quarters
4
With ROCE of 11.77%, it has a expensive valuation with a 3.04 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
USD 24,583 Million (Mid Cap)
33.00
NA
0.98%
0.21
10.82%
3.44
Revenue and Profits:
Net Sales:
1,496 Million
(Quarterly Results - Dec 2025)
Net Profit:
194 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-14.78%
0%
-14.78%
6 Months
-14.13%
0%
-14.13%
1 Year
-3.54%
0%
-3.54%
2 Years
-8.22%
0%
-8.22%
3 Years
20.14%
0%
20.14%
4 Years
-1.92%
0%
-1.92%
5 Years
16.58%
0%
16.58%
STERIS Plc (Ireland) for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.78%
EBIT Growth (5y)
12.31%
EBIT to Interest (avg)
9.63
Debt to EBITDA (avg)
1.94
Net Debt to Equity (avg)
0.29
Sales to Capital Employed (avg)
0.61
Tax Ratio
23.19%
Dividend Payout Ratio
35.14%
Pledged Shares
0
Institutional Holding
99.54%
ROCE (avg)
9.57%
ROE (avg)
9.68%
Valuation key factors
Factor
Value
P/E Ratio
33
Industry P/E
Price to Book Value
3.43
EV to EBIT
25.05
EV to EBITDA
16.99
EV to Capital Employed
2.96
EV to Sales
4.58
PEG Ratio
2.30
Dividend Yield
0.97%
ROCE (Latest)
11.82%
ROE (Latest)
10.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 144 Schemes (38.21%)
Foreign Institutions
Held by 310 Foreign Institutions (31.85%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
1,496.20
1,370.60
9.16%
Operating Profit (PBDIT) excl Other Income
398.90
376.50
5.95%
Interest
14.90
19.10
-21.99%
Exceptional Items
-3.60
-6.10
40.98%
Consolidate Net Profit
194.40
173.40
12.11%
Operating Profit Margin (Excl OI)
185.10%
182.90%
0.22%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 9.16% vs -1.79% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 12.11% vs 23.07% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
5,459.50
5,138.70
6.24%
Operating Profit (PBDIT) excl Other Income
1,462.70
1,473.10
-0.71%
Interest
86.30
144.40
-40.24%
Exceptional Items
-119.00
-69.80
-70.49%
Consolidate Net Profit
611.60
553.30
10.54%
Operating Profit Margin (Excl OI)
180.70%
176.70%
0.40%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 6.24% vs 3.65% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 10.54% vs 422.97% in Mar 2024
About STERIS Plc (Ireland) 
STERIS Plc (Ireland)
Pharmaceuticals & Biotechnology
Steris plc, formerly Steris Ltd, is a provider of infection prevention and other procedural products and services. The Company offers a mix of capital equipment products, such as sterilizers and washers, surgical tables, lights and equipment management systems and connectivity solutions, such as operating room integration; consumable products, such as detergents and gastrointestinal endoscopy accessories and other products; services, including equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory services and outsourced reprocessing. The Company operates through four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. It’s Corporate and other segment includes the Defense and Industrial business unit. The Company serves the customers in the United Kingdom, the United States and many other countries throughout the world.
Company Coordinates 
Company Details
Block a Riverside IV, 70 Sir John Rogerson's Quay DUBLIN None : 2
Registrar Details






